Skip to main content Skip to section navigation Skip to footer

XORTX Therapeutics Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Overview
    • XRx-026 for Gout
    • XRx-008 for Autosomal Dominant Polycystic Kidney Disease
    • XRx-101 for Coronavirus/COVID-19
    • 225 for Type 2 Diabetic Nephropathy
    • Publications
  • Technology
  • News & Media
    • Press Releases
    • Events
    • In the News
  • Investors
    • Overview
    • News & Events
    • Presentations
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR+
    • Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • In the News
Jul 07, 2022 7:00am EDT

XORTX Announces Pre-Phase 3 Meeting Request with US Food and Drug Administration (FDA)

Jun 21, 2022 7:00am EDT

XORTX Announces “Fireside Chat” with XORTX CEO

Jun 13, 2022 8:54am EDT

XORTX to Present at BIO International Convention 2022

Jun 08, 2022 7:00am EDT

XORTX to Present at LD Micro Invitational 2022

Jun 06, 2022 7:00am EDT

XORTX Welcomes New Member to the Board of Directors and Appoints Chair

May 25, 2022 8:00am EDT

XORTX to Present at H. C. Wainwright Global Investment Conference 2022

May 05, 2022 7:00am EDT

XORTX Opens an IND for XRx-008 Program for Autosomal Dominant Polycystic Kidney Disease

May 03, 2022 7:00am EDT

XORTX Initiates Dosing of Human Subjects in the XRX-OXY-101 Clinical Trial

Apr 20, 2022 7:00am EDT

XORTX Receives Small and Medium Enterprise Status for the European Union

Apr 12, 2022 7:00am EDT

XORTX Receives No Objection Letter from Health Canada

  • arrow_back
  • 1…
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • …18
  • arrow_forward
rss_feed News RSS
©2025 XORTX Therapeutics Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap